Search | Clinical Trials Finder

Conditions: Substance Use Disorder, Posttraumatic Stress Disorder
Interventions: Prolonged Exposure with Contingency Management, Standard Care; Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Farmington, Connecticut • Hartford, Connecticut • New Britain, Connecticut

Conditions: Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Diseases, Langerhans-Cell Histiocytosis, Hematologic Diseases
Interventions: Stem Cell Transplant, Myeloablative conditioning regimen; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Colon Lesions
Interventions: Peptide application; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Disease
Interventions: Plastic Scintillation Detectors; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypoxia
Interventions: Mixtures of nitrogen, air, and carbon dioxide; Combination Product
Lead sponsor: Gabi SmartCare; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions: ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox, flow cytometry, immunoenzyme technique; Drug · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Celiac Disease, Gluten Sensitivity, Non-celiac Gluten Sensitivity
Interventions: Bovine colostrum, Placebo; Dietary Supplement
Lead sponsor: Milky Way Life Sciences LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cataract
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma, Melanocytic Lesion, Adult
Interventions: Two photon microscopy imaging; Device
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Victor, New York

Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions: IFx-Hu2.0; Biological
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Brandon, Florida

Conditions: Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
Interventions: LUM Imaging System; Combination Product
Lead sponsor: Lumicell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anemia, Sickle Cell
Interventions: ARU-1801; Genetic
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cancer of the Gastrointestinal, Genitourinary or Gynecologic Systems
Interventions: Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD); Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dental Caries
Interventions: Enamel Pro, Duraphat, Vanish, Placebo; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Specific Phobia
Interventions: Exposure therapy; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Interventions: Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice, Everolimus, Ganitumab, Ifosfamide, Irinotecan, Pazopanib, Polyethylene Glycol, Temozolomide, Temsirolimus, Therapeutic Conventional Surgery, Vincristine; Drug · Device · Biological + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colonic Polyps, Adenomatous Polyps
Interventions: Ex vivo module, In vivo practice-base learning phase; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 2
States / cities: Stanford, California • Ann Arbor, Michigan

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more

Conditions: Cystic Fibrosis
Interventions: RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5; Device · Other
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more

Conditions: Liver Transplantation, Kidney Transplantation
Interventions: rTPA Treatment, No TPA Treatment; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor
Interventions: lapatinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Fanconi Anemia
Interventions: RP-L102; Biological
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2038
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Written Exposure Therapy, Trauma-focused Cognitive Behavior Therapy; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma (SCC) of the Oral Cavity
Interventions: Reflectance Confocal Microscopy; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 2 more

Search by objective public record fields.

Integrated Treatment for Posttraumatic Stress Disorder and Substance Abuse in Young Adults

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

A Phase I In-Vivo Peptide Applied in the Right Colon

In Vivo Dosimetry During Prostate Cancer Radiotherapy

In Vivo Pulse Oximeter Validation Study

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Bovine Colostrum to Prevent Absorption of Gluten

Dynamic Light Scattering for Studying Lens Aging and Cataract Formation

Two-photon Fluorescence Microscopy of Dermatologic Biopsies

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

Gene Transfer for Patients With Sickle Cell Disease

Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy

In Vivo Comparison of Salivary Fluoride Levels Following the Application of Different 5% NaF Varnishes

The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Practice-Based Learning to Predict Polyp Histology at Colonoscopy

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

Adaptation and Randomized Controlled Trial of Written Exposure Therapy for Adolescents

Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology